Title: Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017 Document date: 2017_11_7
ID: roslkxeq_327
Snippet: Median survival time of toceranib-treated patients was 359 days (range 66-1024 days) which is substantially higher than 71 days (median; 95% CI: 6-136 days) or 82 days (95% CI: 0-247 days) previously reported with a variety of non-TKI therapies......
Document: Median survival time of toceranib-treated patients was 359 days (range 66-1024 days) which is substantially higher than 71 days (median; 95% CI: 6-136 days) or 82 days (95% CI: 0-247 days) previously reported with a variety of non-TKI therapies.
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date